MX2015008847A - Composiciones inmunogenicas de virus de influenza y usos de las mismas. - Google Patents

Composiciones inmunogenicas de virus de influenza y usos de las mismas.

Info

Publication number
MX2015008847A
MX2015008847A MX2015008847A MX2015008847A MX2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A
Authority
MX
Mexico
Prior art keywords
influenza virus
rna
epitope
immunogenic compositions
component
Prior art date
Application number
MX2015008847A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Geall
Sylvie Carine Bertholet Girardin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015008847A publication Critical patent/MX2015008847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2015008847A 2013-01-10 2014-01-10 Composiciones inmunogenicas de virus de influenza y usos de las mismas. MX2015008847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751077P 2013-01-10 2013-01-10
PCT/EP2014/050414 WO2014108515A1 (en) 2013-01-10 2014-01-10 Influenza virus immunogenic compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2015008847A true MX2015008847A (es) 2015-10-30

Family

ID=49956176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008847A MX2015008847A (es) 2013-01-10 2014-01-10 Composiciones inmunogenicas de virus de influenza y usos de las mismas.

Country Status (10)

Country Link
US (1) US20140193484A1 (enExample)
EP (1) EP2943221A1 (enExample)
JP (2) JP2016506416A (enExample)
CN (2) CN104902925A (enExample)
AU (2) AU2014204826A1 (enExample)
CA (1) CA2897752A1 (enExample)
HK (1) HK1214962A1 (enExample)
MX (1) MX2015008847A (enExample)
RU (1) RU2015132962A (enExample)
WO (1) WO2014108515A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4241785A3 (en) 2011-09-20 2023-09-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA3177878A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016184822A1 (en) 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3365007A4 (en) * 2015-10-22 2019-07-03 ModernaTX, Inc. WIDE SPECTRUM VACCINE AGAINST INFLUENZA VIRUS
CA3010974A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
CN105664149A (zh) * 2016-02-24 2016-06-15 华东理工大学 一种多抗原流感通用疫苗及其制备方法
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
BR112019026615B1 (pt) * 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3109165A1 (en) * 2018-08-17 2020-02-20 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
JP2022501367A (ja) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
WO2020127730A1 (en) 2018-12-20 2020-06-25 Intervet International B.V. Prime-boost vaccination regimen
JP2023502400A (ja) * 2019-11-18 2023-01-24 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン がん免疫療法のために常在型樹状細胞を超活性化する刺激
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CN118647600A (zh) 2021-12-16 2024-09-13 爱康泰生治疗公司 用于脂质纳米颗粒制剂的脂质
TWI880664B (zh) * 2023-03-10 2025-04-11 財團法人國家衛生研究院 流感病毒免疫原性組合物及使用其的方法
AU2024270076A1 (en) * 2023-05-10 2025-11-27 Seqirus Inc. Combination vaccine

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2204254C (en) 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6090619A (en) 1997-09-08 2000-07-18 University Of Florida Materials and methods for intracellular delivery of biologically active molecules
HUP0202846A3 (en) 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
EP1361889A1 (en) 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Novel vaccine
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
DK1585812T3 (en) * 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
US7410795B2 (en) 2002-12-23 2008-08-12 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP2037959B1 (en) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2008039267A2 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
AU2007296489B2 (en) * 2006-09-12 2013-07-04 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
EP2131848A4 (en) * 2007-02-16 2012-06-27 Merck Sharp & Dohme COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
US20110280949A1 (en) * 2008-08-06 2011-11-17 Padma Malyala Microparticles for use in immunogenic compositions
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US20120164176A1 (en) * 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
JP5988492B2 (ja) * 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9163068B2 (en) * 2009-11-03 2015-10-20 The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer Influenza virus recombinant proteins
WO2012082165A1 (en) * 2010-01-24 2012-06-21 Novartis Ag Irradiated biodegradable polymer microparticles
EP3449910A1 (en) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
LT2590676T (lt) 2010-07-06 2016-10-25 Glaxosmithkline Biologicals Sa Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
DK2591114T3 (en) * 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
SI3243526T1 (sl) * 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
MX2013000163A (es) * 2010-07-06 2013-03-05 Novartis Ag Metodos y composiciones inmunogenicas derivadas de norovirus.
CN103153284B (zh) * 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
FI4043040T3 (fi) 2010-08-31 2023-04-04 Glaxosmithkline Biologicals Sa Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
WO2012034025A2 (en) * 2010-09-09 2012-03-15 Virginia Commonwealth University Human cytomegalovirus vaccine
BR112013008700B8 (pt) * 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
EP3527224B1 (en) * 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
DK3275892T3 (da) * 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa Præfusions-rsv-f-antigener
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CN103764121A (zh) * 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
CA2840965C (en) * 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
ES2657547T3 (es) 2011-07-06 2018-03-05 Glaxosmithkline Biologicals Sa Emulsiones aceite en agua que contienen ácidos nucleicos
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
LT2750707T (lt) 2011-08-31 2019-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
AU2012322704B2 (en) * 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
US9504747B2 (en) * 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Also Published As

Publication number Publication date
EP2943221A1 (en) 2015-11-18
AU2018260983A1 (en) 2018-12-06
JP2018035195A (ja) 2018-03-08
US20140193484A1 (en) 2014-07-10
CA2897752A1 (en) 2014-07-17
HK1214962A1 (zh) 2016-08-12
WO2014108515A1 (en) 2014-07-17
AU2014204826A1 (en) 2015-07-09
JP2016506416A (ja) 2016-03-03
RU2015132962A (ru) 2017-02-14
CN109045294A (zh) 2018-12-21
CN104902925A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2018009990A (es) Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2013054199A3 (en) Cmv antigens and uses thereof
IN2014KN03063A (enExample)
MX2015010783A (es) Composicion de vacuna.
UY36006A (es) Construcciones de proteína uspa2 y usos de las mismas.
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
MX340796B (es) Composiciones y procedimientos antigenicos del virus respiratorio sincitial.
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
MX2014011712A (es) Composiciones antigenas y procedimientos.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
MX2019007924A (es) Vacunas contra la influenza.
IN2014DN09445A (enExample)
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
IN2015DN03925A (enExample)